Vincent Launay-Vacher

Summary

Country: France

Publications

  1. ncbi [How to adjust the dose of drugs in chronic kidney disease?]
    Vincent Launay-Vacher
    Service ICAR, Service de Nephrologie, Groupe Hospitalier La Pitié Salpêtrière, AP HP, 75013 Paris
    Rev Prat 62:309-11, 314-5. 2012
  2. ncbi Drug management of prostate cancer: prevalence and consequences of renal insufficiency
    Vincent Launay-Vacher
    Department of Nephrology Pr Deray, Hopital Pitie Salpetriere, Paris, France
    Clin Genitourin Cancer 7:E83-9. 2009
  3. ncbi Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Urol Oncol 29:492-4. 2011
  4. ncbi Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group
    Vincent Launay-Vacher
    Service ICAR, Service de Nephrologie, Hopital Pitie Salpetriere, Paris, France
    Semin Nephrol 30:548-56. 2010
  5. ncbi Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
    Vincent Launay-Vacher
    ICAR, Department of Nephrology, Hopital Pitie Salpetriere, 83 Boulevard de l hopital, 75013 Paris, France
    Cancer Chemother Pharmacol 61:903-9. 2008
  6. ncbi [Chemotherapy and renal toxicity]
    Vincent Launay-Vacher
    Service de Nephrologie, Hopital de la Pitie Salpetriere, 83, Boulevard de l Hopital, 75013 Paris, France
    Bull Cancer 95:F96-103. 2008
  7. ncbi Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Breast Cancer Res Treat 124:745-53. 2010
  8. ncbi Hypertension and proteinuria: a class-effect of antiangiogenic therapies
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Anticancer Drugs 20:81-2. 2009
  9. ncbi Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Crit Rev Oncol Hematol 70:124-33. 2009
  10. ncbi Lung cancer and renal insufficiency: prevalence and anticancer drug issues
    Vincent Launay-Vacher
    Department of Nephrology, Pr Deray, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Lung 187:69-74. 2009

Collaborators

Detail Information

Publications56

  1. ncbi [How to adjust the dose of drugs in chronic kidney disease?]
    Vincent Launay-Vacher
    Service ICAR, Service de Nephrologie, Groupe Hospitalier La Pitié Salpêtrière, AP HP, 75013 Paris
    Rev Prat 62:309-11, 314-5. 2012
    ..However, some information sources exist, reliable, updated, and easily accessible...
  2. ncbi Drug management of prostate cancer: prevalence and consequences of renal insufficiency
    Vincent Launay-Vacher
    Department of Nephrology Pr Deray, Hopital Pitie Salpetriere, Paris, France
    Clin Genitourin Cancer 7:E83-9. 2009
    ..A national multicenter study from 15 cancer centers in France analyzed IRMA data on patients with prostate cancer...
  3. ncbi Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Urol Oncol 29:492-4. 2011
    ..e., glomerular filtration rate (GFR). We report on the evolution of GFR in patients receiving antiangiogenic therapy after unilateral nephrectomy for kidney cancer...
  4. ncbi Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group
    Vincent Launay-Vacher
    Service ICAR, Service de Nephrologie, Hopital Pitie Salpetriere, Paris, France
    Semin Nephrol 30:548-56. 2010
    ..This reduced survival has been hypothesized to be related to the cardiovascular complications of KD or as a consequence of inappropriate drug dosage adjustment...
  5. ncbi Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
    Vincent Launay-Vacher
    ICAR, Department of Nephrology, Hopital Pitie Salpetriere, 83 Boulevard de l hopital, 75013 Paris, France
    Cancer Chemother Pharmacol 61:903-9. 2008
    ....
  6. ncbi [Chemotherapy and renal toxicity]
    Vincent Launay-Vacher
    Service de Nephrologie, Hopital de la Pitie Salpetriere, 83, Boulevard de l Hopital, 75013 Paris, France
    Bull Cancer 95:F96-103. 2008
    ....
  7. ncbi Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Breast Cancer Res Treat 124:745-53. 2010
    ..Both issues seem to be slightly but significantly more important in patients with bone metastases as compared to patients with a non-metastatic disease...
  8. ncbi Hypertension and proteinuria: a class-effect of antiangiogenic therapies
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Anticancer Drugs 20:81-2. 2009
    ..Clinicians should thus be aware of such a 'class effect' to appropriately monitor and treat their patients, regardless of which antiangiogenic drug is used...
  9. ncbi Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study
    Vincent Launay-Vacher
    Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Crit Rev Oncol Hematol 70:124-33. 2009
    ..Anticancer drugs used may be nephrotoxic or need dosage adjustment in a high number of cases...
  10. ncbi Lung cancer and renal insufficiency: prevalence and anticancer drug issues
    Vincent Launay-Vacher
    Department of Nephrology, Pr Deray, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Lung 187:69-74. 2009
    ..Lung cancer patients often present with anemia, which was not associated with the presence of RI...
  11. ncbi Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients
    Vincent Launay-Vacher
    Department of Nephrology, Pitié Salpetricre Hospital, Paris, France
    Med Sci Monit 10:CR209-12. 2004
    ..The high frequency of this disease in the general US population has been assessed in the NHANES III study. However, the frequency of chronic renal insufficiency among cancer patients remains unclear...
  12. ncbi Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study
    Vincent Launay Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Cancer 110:1376-84. 2007
    ..The results from this study of nearly 5,000 patients demonstrated the high prevalence of renal impairment in a population of patients with solid tumors...
  13. ncbi Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    Nephrol Dial Transplant 20:743-6. 2005
    ..However, controlled data are sparse on the long-term renal tolerability of TDF at the currently approved daily dose of 300 mg in treatment-naive HIV-infected patients...
  14. ncbi Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Kidney Int 66:1153-8. 2004
    ..We report a complete analysis on the renal tolerance of ADV at the currently approved dose of 10 mg daily for the treatment of chronic hepatitis B...
  15. ncbi Antiretroviral drugs and the kidney: dosage adjustment and renal tolerance
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Curr Pharm Des 10:4071-9. 2004
    ..6 to 1%). Therefore, administration of antiretroviral drugs in human immunodeficiency virus (HIV) patients with nephropathy is not uncommon...
  16. ncbi [Anticancer drug-induced nephrotoxicity]
    Corinne Isnard-Bagnis
    Service de Nephrologie, Hopital Pitie Salpetriere, 83, Boulevard de l Hopital, 75013 Paris, France
    Nephrol Ther 1:101-14. 2005
    ....
  17. ncbi Drug-induced diabetes mellitus
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Expert Opin Drug Saf 4:1097-109. 2005
    ..To review the medications that influence glucose metabolism with a focus on hypertensive, transplant and HIV-infected patient populations...
  18. ncbi Clinical review: use of vancomycin in haemodialysis patients
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Crit Care 6:313-6. 2002
    ..The aim of the present review is to establish guidelines for handling this drug in such patients. We indicate how and when plasma concentrations of vancomycin should be determined in dialysis patients...
  19. ncbi Renal safety of tenofovir in HIV treatment-experienced patients
    Hassane Izzedine
    Department of Nephrology, , Paris, France
    AIDS 18:1074-6. 2004
    ..Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation...
  20. ncbi Antiretroviral and immunosuppressive drug-drug interactions: an update
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Kidney Int 66:532-41. 2004
    ....
  21. ncbi Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study
    Nicolas Janus
    Department of Nephrology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Eur J Radiol 73:357-9. 2010
    ..The FINEST study (FIbrose Néphrogénique SysTémique) was designed to determine the prevalence of NSF after magnetic resonance imaging (MRI) in French RI patients...
  22. ncbi FHD: an index to evaluate drug elimination by hemodialysis
    Vincent Launay-Vacher
    Department of Nephrology, , Paris, France
    Am J Nephrol 25:342-51. 2005
    ..F(HD )could be the index of choice to determine when to administer a drug, before or after the session, in hemodialysis patients...
  23. ncbi Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis
    Jérôme Tourret
    Nephrology Department, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Clin Infect Dis 45:779-84. 2007
    ..We analyzed highly active antiretroviral therapy (HAART) prescribing practices for human immunodeficiency virus (HIV)-infected patients undergoing hemodialysis in France...
  24. ncbi [Is dialysis efficient in the prevention of ionic contrast agent-induced nephropathy?]
    Svetlana Karie
    Service de Nephrologie, Groupe hospitalier Pitié Salpêtrière 83, boulevard de I hôpital, 75013 Paris, France
    Presse Med 34:803-8. 2005
    ..No data yet justify a conclusion that a hemodialysis session immediately after injection of a CM in chronic dialysis patients might be helpful...
  25. ncbi Antiviral drug-induced nephrotoxicity
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Am J Kidney Dis 45:804-17. 2005
    ..In this article, we review the pathogenesis of antiviral drug-induced kidney injury, common nephrotoxic renal syndromes, and strategies for preventing kidney injury...
  26. ncbi Oculorenal manifestations in systemic autoimmune diseases
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Am J Kidney Dis 43:209-22. 2004
    ..Examination of the eye and kidney should be performed routinely in those diseases. This article reviews the major types of oculorenal manifestations in systemic autoimmune diseases...
  27. ncbi Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study
    Svetlana Karie-Guigues
    Service de Nephrologie, Groupe Hospitalier de la Pitié Salpêtrière, Paris, France
    Liver Transpl 15:1083-91. 2009
    ..It seems likely that early intervention for CNI reduction is best for reducing the use of CNIs in the long term...
  28. ncbi [Drugs renal toxicity]
    Svetlana Karie
    Service de Nephrologie, Hopital Pitie Salpetriere, Boulevard de l Hopital, Paris, France
    Nephrol Ther 6:58-74. 2010
    ..Risk factors are also listed, such as high-risk populations, identification and elimination of risk factors, and drug dosage adjustment in patients with baseline abnormal renal function...
  29. ncbi Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency
    Elena Ledneva
    Information Conseil Adaptation Renal, Department of Nephrology, Hopital Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Radiology 250:618-28. 2009
    ..This review surveys the literature with the purpose of clarifying the renal effects of gadolinium-based CM in patients with renal insufficiency...
  30. ncbi Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, 83, Boulevard de l Hopital, 75013 Paris, France
    Int J Cardiol 101:9-17. 2005
    ....
  31. ncbi Lymphadenopathy and proteinuria
    Svetlana Karie
    Department of Nephrology, , Paris, France
    Nephrol Dial Transplant 19:739-41. 2004
  32. ncbi Drug-induced Fanconi's syndrome
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Am J Kidney Dis 41:292-309. 2003
    ..Acquired renal tubular defects resulting in FS also have been described in association with many exogenous agents, whether administered or accidentally ingested. This review concentrates on drug-induced FS...
  33. ncbi [Drud-induced nephrotoxicity: Bibliography from January 2003 to December 2005]
    Svetlana Karie
    ICAR, Service de Nephrologie, Groupe Hospitalier de la Pitié Salpêtrière, 83, Boulevard de l Hopital, 75015 Paris, France
    Nephrol Ther 2:368-78. 2006
    ..In this article, we present an updated version of the bibliography containing the case reports of nephrotoxicity published in the international literature from January 2003 to December 2005...
  34. ncbi Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Clin Pharmacokinet 44:221-35. 2005
    ..In the meantime, it could be generally advised to administer all antitubercular drugs after the haemodialysis session, even though some drugs are known to be non-dialysable...
  35. ncbi Ear and kidney syndromes: molecular versus clinical approach
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Kidney Int 65:369-85. 2004
    ..Here, we describe ear and kidney clinical syndromes and their molecular expression...
  36. ncbi Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    J Pain 6:137-48. 2005
    ..Perspective This well-known treatment strategy now adapted for use in patients with renal insufficiency should secure and rationalize pain treatment in those patients...
  37. ncbi [Drug-induced nephrotoxicity: bibliography from January 2003 to December 2004]
    Svetlana Karie
    Service de Nephrologie, Groupe Hospitalier Pitie Salpetriere, 83, Boulevard de l Hopital, 75015 Paris, France
    Nephrol Ther 1:285-95. 2005
    ..In this article, we present an updated version of the bibliography containing the case reports of nephrotoxicity published in the international literature from January 2003 to December 2004...
  38. ncbi Renal tubular drug transporters
    Vincent Launay-Vacher
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Nephron Physiol 103:p97-106. 2006
    ..Detailed information concerning molecular and cellular aspects of drug transporters expressed in the kidney has facilitated studies of the mechanisms underlying renal disposition as well as transporter-mediated drug interactions...
  39. ncbi Abnormal blood pressure circadian rhythm: a target organ damage?
    Hassane Izzedine
    Nephrology Department, Pitie Salpetriere Hospital, 47 83, Blvd de l Hopital, 75013, Paris, France
    Int J Cardiol 107:343-9. 2006
    ..These data suggest that patients in whom blood pressure decreases during the night incur less damage to their brain, kidneys, heart, and blood vessels than people with elevated nocturnal BP...
  40. ncbi Evaluation of current practice: management of chemotherapy-related toxicities
    Stéphanie Lheureux
    Department of Clinical Research, Pitie Salpetriere Hospital, Paris, France
    Anticancer Drugs 22:919-25. 2011
    ..Albumin, creatinine clearance and lymphocyte should be routinely monitored at baseline to manage CT and to prevent their toxicities...
  41. ncbi Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Clin Pharmacol Ther 71:503-7. 2002
    ..Severe symptomatic hyponatremia induced by the syndrome of inappropriate secretion of antidiuretic hormone should be considered a rare but possible complication associated with ACE inhibitor therapy...
  42. ncbi Drug-induced glomerulopathies
    Hassan Izzedine
    Pitie Salpetriere Hospital, Department of Nephrology, 47 83 boulevard de l Hopital, 75013 Paris, France
    Expert Opin Drug Saf 5:95-106. 2006
    ..This is, for instance, reflected in the fact that patients with drug-induced nephritic syndrome frequently have the HLA-B8 and DR3 antigens. In depth information is provided for the previously mentioned disorders...
  43. ncbi Pharmacokinetics of tenofovir in haemodialysis
    Hassane Izzedine
    Department of Nephrology, , Paris, France
    Nephrol Dial Transplant 18:1931-3. 2003
  44. ncbi Eye and kidney: from clinical findings to genetic explanations
    Hassane Izzedine
    Nephrology and Ophthalmology Departments, Pitie-Salpetriere Hospital, Paris, France
    J Am Soc Nephrol 14:516-29. 2003
  45. ncbi Why is a shrunken bladder and a nephrotic kidney an expression of the same disease?
    Sophie Georgin-Lavialle
    Department of Nephrology, , Paris, France
    Nephrol Dial Transplant 19:3193-5. 2004
  46. ncbi Colony stimulating factors (CSF) biosimilars. Progress?
    Florian Scotte
    European Hospital Georges Pompidou, 20, rue Leblanc, 75015 Paris, France
    Target Oncol 7:S17-24. 2012
    ..Many questions arise in connection with the marketing of several biosimilar drugs in the field of hematopoietic growth factors of white and red cells. Many of them should be discussed...
  47. ncbi Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis
    Hassane Izzedine
    Kidney Int 64:2324. 2003
  48. ncbi Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis
    Juliette Thariat
    J Clin Oncol 26:4223-5. 2008
  49. ncbi International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency
    Stuart M Lichtman
    Memorial Sloan Kettering Cancer Centre, New York, USA
    Eur J Cancer 43:14-34. 2007
    ..Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are needed in order to maximise efficacy whilst avoiding unacceptable toxicity...
  50. ncbi Atazanavir: a novel inhibitor of HIV-protease in haemodialysis
    Hassane Izzedine
    Nephrol Dial Transplant 20:852-3. 2005
  51. ncbi [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]
    Svetlana Karie
    , , Paris
    Presse Med 35:219-29. 2006
    ..Their effectiveness in cardiovascular prevention in this population has not been demonstrated to date. Results about statin-induced kidney protection are encouraging but further and more specific studies are needed...
  52. ncbi Thrombocytopenia induced by nicotinamide in hemodialysis patients
    Jacques B Rottembourg
    Kidney Int 68:2911-2. 2005
  53. ncbi Hemodialysis and ADAMTS-13
    Hassane Izzedine
    Blood Purif 22:480. 2004
  54. ncbi Beta-blocker-induced quadriparesis
    Hassane Izzedine
    Ann Intern Med 141:W62. 2004
  55. ncbi Pharmacokinetics of tramadol in a hemodialysis patient
    Hassane Izzedine
    Nephron 92:755-6. 2002
  56. ncbi Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient
    Nader Bassilios
    Nephrol Dial Transplant 17:531-2. 2002